长春瑞滨联合替吉奥治疗蒽环类和紫杉类耐药复发转移性乳腺癌的临床观察  

Clinical Observation of Vinorelbine Combined with S-1for Anthracycline and Taxane-resistant Metastatic Breast Cancer

作　　者：文玲波[1] 杨兰平[1] 

机构地区：[1]柳州医学高等专科学校第二附属医院化疗科,545006

出　　处：《实用癌症杂志》2013年第3期253-255,共3页The Practical Journal of Cancer

摘　　要：目的观察长春瑞滨联合替吉奥治疗蒽环类和紫杉类耐药的复发转移性乳腺癌(anthracycline and taxaneresistant metaststic breast cancer,ATRMBC)的疗效和不良反应。方法 32例ATRMBC患者采用长春瑞滨(25 mg/m2静脉滴注,第1、8天)联合替吉奥(每天80 mg/m2,分2次口服,连服1～14天)治疗,3周为1个周期。治疗2个周期后按RE-CIST标准评价疗效及按WHO标准评价不良反应。结果 32例患者均可评价疗效和不良反应,其中完全缓解(CR)3例,部分缓解(PR)14例,稳定(SD)9例,进展(PD)6例。客观有效率(ORR=CR+PR)为53.1%,疾病控制率(DCR=CR+PR+SD)为81.3%。无进展生存期(progression-free survival,PFS)中位生存时间为8个月。主要不良反应为骨髓抑制及胃肠道反应,以Ⅰ、Ⅱ度为主,均可耐受。结论长春瑞滨联合替吉奥是治疗ATRMBC患者的有效方案,患者对不良反应能够耐受。Objective To observe the efficacy and toxicities of vinorelbine（NVB） combined with S-1 for patients with anthracycline and taxane-resistant metastatic breast cancer（ATRMBC）.Methods 32 ATRMBC patients were given intravenous 25 mg/m2 NVB at day 1 and day 8,and oral 80 mg/m2 S-1 twice every day at day 1 to 14.Every 3 weeks was 1 cycle.The efficacy was evaluated by RECIST standards and the toxicities were evaluated by WHO standards after 2 cycles.Results Efficacy and toxicities could be evaluated in 32 patients,and there were 3 cases of complete remission（CR）,14 cases of partial remission（PR）,9 cases of stability（SD） and 6 cases of disease progression（PD）.The objective response rate（ORR=CR＋PR） was 53.1% and disease control rate（DCR=CR＋PR＋SD）was 81.3%.Median time to progression-free survival（PFS） was 8 months.The main toxicity was myelosuppression and gastrointestinal reactions,which were mainlyⅠ-Ⅱdegree,and could be well-tolerated.Conclusion NVB combined with S-1 is effective for ATRMBC patients with good tolerance.

关 键 词：晚期乳腺癌 耐药 长春瑞滨 替吉奥 疗效 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]